[ad_1]
Men who have stable coronary artery disease who also take Viagra can live longer and also have a reduced risk of having another heart attack compared to those who suffer from the disease but do not take the erectile dysfunction drug, according to the results of a new study published in the Journal of the American College of Cardiology.
Researchers at Karolinska Institutet in Sweden compared the effects of different erectile dysfunction drugs in men with stable coronary artery disease. All participants had suffered a heart attack, had undergone balloon dilation (a cardiac catheterization procedure), or had bypass surgery within six months of starting treatment for erectile dysfunction.
Collecting data from patient records, medications, and causes of death, the researchers examined 16,500 men treated with PDE5 inhibitors, such as Viagra or Cialis, while just under 2,000 of those were treated with PDE5 inhibitors, such as Viagra or Cialis. participants received alprostadil, an injectable drug used to treat erectile dysfunction.
In the end, the researchers found that men treated with PDE5 inhibitors lived longer and had a lower risk of another heart attack, heart failure, balloon dilation and bypass surgery than those who received L ‘alprostadil.
URINALS CAN SPREAD CORONAVIRUSES, STUDY RESULTS
“The protection was dose-dependent, so the more frequent the dose of PDE5 inhibitor, the lower the risk,” notes a press release on the results.
“Potency issues are common in older men and now our study also shows that PDE5 inhibitors may protect against heart attacks and prolong life,” said Dr Martin Holzmann, assistant professor in the Department of Medicine at Karolinska Institutet who led the study, in a report.
PENIS MICROBES MAY PLAY A ROLE IN COMMON VAGINAL INFECTIONS
The researchers speculated that the results could be due to the fact that certain erectile dysfunction drugs like Viagra lower blood pressure, as high blood pressure is a risk factor for heart disease. That said, Holzmann noted that the study was observational and more research was needed on the topic.
“This suggests that there is a causal relationship, but a registry study cannot answer that question,” Holzmann said in a statement. “It is possible that those who received PDE5 inhibitors were healthier than those who took alprostadil and therefore had a lower risk. To determine if this is the drug that reduces the risk, we would need to randomly divide the patients into two groups, the one taking PDE5. and one that doesn’t. The results we have now give us very good reasons to embark on such a study. “
[ad_2]
Source link